PRESS RELEASES

Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on...
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a...
The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on the Directed Share Issue of 2,601,732...
The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby...
The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The...
The Directed Share Issue comprises 2,601,732 new shares issued at a subscription price of SEK 14.99 per share, which means that the Company will raise...
LSX Nordic, Copenhagen, Denmark, 6-7 September Biostock Investerarevent, digital, 14 September Nordic Life Science Days, Malmö, Sweden, 28-29 September...
CEO Einar Pontén comments: “Through long-term and systematic work, we are now almost ready to start clinical trials. We have mitigated many...
Dr. Helena Bergström is an experienced clinician that previously also has been involved in research of sex-and gender differences in medicine, drug...
The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) has been carried out in collaboration with the contract...

INVESTOR RELATIONS